Certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-28 and is reviewed periodically as new material appears.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
==== 1998 congressional campaign ==== In 1998, Yates opted to forgo reelection, and Pritzker ran in the Democratic primary to succeed him, reconstituting his campaign committee in April 1997. Also running in the primary were state representative Jan Schakowsky and state senator Howard W. Carroll. The district covered the northern lakefront of Chicago, as well as the suburbs of Evanston and Skokie. It had a large Jewish electorate and had long been regarded as the "Jewish seat" in Illinois's congressional delegation. Yates was Jewish, as were all three Democratic contenders to succeed him. The district had been described as being among the most liberal in the country. Journalist James Ylisela Jr. observed that Pritzker, Schakowsky, and Carroll largely all ran on platforms aligned with the "liberal Democratic Party agenda" that Yates had championed. But the Chicago Tribune wrote that Pritzker and Carroll ran on more moderate platforms than Schakowsky, and therefore potentially wound up competing with each other for many of the same voters. At the time, the election was one of the most expensive congressional primaries in U.S. history, and Pritzker spent nearly $1 million of his own money on his campaign. This included $500,000 on television ads in the Chicago market. He finished third among five candidates in the Democratic primary, with 20.5% of the vote to Schakowsky's 45.1% and Carroll's 34.4%. Schakowsky went on to represent the district for 28 years, retiring after the 2026 election.
The first aircraft carrying troopers from the 2–325th touched down at Point Salines 17 hours after H-Hour notification. In March 1988, a brigade task force made up of two battalions from the 504th Infantry and 3d Battalion (Airborne), 505th Infantry, conducted a parachute insertion and air/land operation into Honduras as part of Operation Golden Pheasant. The deployment was billed as a joint training exercise, but the paratroopers were ready to fight. The deployment caused the Sandinistas to withdraw to Nicaragua. Operation Golden Pheasant prepared the paratroopers for future combat in an increasingly unstable world.
The UCIL factory was built in 1969 to produce the pesticide Sevin (UCC's brand name for carbaryl) using methyl isocyanate (MIC) as an intermediate. An MIC production plant was added to the UCIL site in 1979. The chemical process employed in the Bhopal plant had methylamine reacting with phosgene to form MIC, which was in turn reacted with 1-naphthol to form the final product, carbaryl. Another manufacturer, Bayer, also used this MIC-intermediate process at the chemical plant once owned by UCC at Institute, West Virginia in the United States. After the Bhopal plant was built, other manufacturers (including Bayer) produced carbaryl without MIC, though at a greater manufacturing cost. UCIL's process differed from the MIC-free routes used elsewhere, in which the same raw materials were combined in a different manufacturing order, with phosgene initially reacting with 1-naphthol to form a chloroformate ester, which was later reacted with methylamine. In the early 1980s, although the demand for pesticides had fallen, production continued leading to an accumulation of unused MIC at the Bhopal site.
Tetrahydrocannabinol (THC) is a cannabinoid found in cannabis. It is the principal psychoactive constituent of Cannabis and one of at least 113 total cannabinoids identified on the plant. Although the chemical formula for THC (C21H30O2) describes multiple isomers, the term THC usually refers to the delta-9-THC isomer with chemical name (−)-trans-Δ9-tetrahydrocannabinol. THC, also known pharmaceutically as dronabinol, is used medically to relieve chemotherapy-induced nausea and HIV/AIDS-related anorexia. Nabiximols, a botanical drug which contains THC, is used medically to treat symptoms of multiple sclerosis, including spasticity and neuropathic pain. THC acts as a partial agonist at CB1 and CB2 cannabinoid receptors. THC can be administered orally, inhaled, or transdermally, with bioavailability and onset varying by route, and is extensively metabolized in the liver to active and inactive metabolites before being excreted in feces and urine. Side effects include red eyes, dry mouth, drowsiness, memory impairment, anxiety, and, with chronic use, cannabinoid hyperemesis syndrome. While human overdose is rare, THC can interact with other drugs and has a complex pharmacokinetic profile.
Strong growth of demand: today, biopharmaceuticals account for about $55–$80 billion, or 15% of the total pharmaceutical market. They are growing by 15% per year, three times faster than LMW drugs, and are expected to pass the $150 billion per year threshold by 2015. Whereas just one out of the world's top ten drugs was a biopharmaceutical in 2001, the number went up to five in 2010 and is expected to increase further to eight by 2016 (see Table 2).
Sources: en.wikipedia.org
Codeine/paracetamol, also called codeine/acetaminophen and co-codamol, is a compound analgesic, comprising codeine phosphate and paracetamol (acetaminophen). Codeine/paracetamol is used for the relief of mild to moderate pain when paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs; such as ibuprofen, aspirin, and naproxen) alone do not sufficiently relieve symptoms. In 2023, it was the 210th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
=== Eukaryotic mRNA turnover === Inside eukaryotic cells, there is a balance between the processes of translation and mRNA decay. Messages that are being actively translated are typically associated with cap-binding and translation initiation factors and with poly(A)-binding protein, which can antagonize deadenylation and decapping and help protect mRNA ends from decay machinery. The balance between translation and decay is reflected in the size and abundance of cytoplasmic structures known as P-bodies. The poly(A) tail of the mRNA is shortened by specialized exonucleases that are targeted to specific messenger RNAs by a combination of cis-regulatory sequences on the RNA and trans-acting RNA-binding proteins. Poly(A) tail removal is thought to disrupt the circular structure of the message and destabilize the cap binding complex. The message is then subject to degradation by either the exosome complex or the decapping complex. In this way, translationally inactive messages can be destroyed quickly, while active messages remain intact. The mechanism by which translation stops and the message is handed-off to decay complexes is not understood in detail. The majority of mRNA decay was believed to be cytoplasmic; however, recently, a novel mRNA decay pathway was described, which starts in the nucleus.
Many children who experience abuse go on to develop an addiction in adolescence or adult life. This pathway towards addiction that is opened through stressful experiences during childhood can be avoided by a change in environmental factors throughout an individual's life and opportunities of professional help. Social and environmental influences include family dynamics, early and adverse experiences, socioeconomic status, peer networks, and cultural norms. Adverse childhood exposures and maladaptive developmental trajectories are robust environmental influences on the development of alcohol use disorder, and adverse childhood experiences are recognized more generally as a social determinant of vulnerability to substance use disorders. Social networks exert a bidirectional influence, while wider sociocultural factors (including public-health control policies and the social determinants of health) shape both exposure and outcome. Because social risk factors are modifiable, prevention that targets them in childhood and adolescence can reduce the risk of later disorder. Together, these levels of analysis present addiction as a dynamic condition emerging from the interaction of neurobiological processes, individual psychological traits and broader social environments. Social factors act largely through chronic stress, peer modeling, socioeconomic constraint and the availability of substances, influencing both the likelihood of exposure and the risk of escalation or relapse.
==== Liquid samples ==== Liquid samples can be sandwiched between two plates of a salt—commonly sodium chloride, but a number of other salts such as potassium bromide or calcium fluoride are sometimes. The plates themselves are transparent in the infrared band, allowing the IR effects of the sample itself to be seen through them without substantial interference. If the IR spectrum of the plates themselves is known, this "background spectrum" can be subtracted from the experimental spectrum of the sample to remove artifacts and allow the spectrum of the substance of interest to be seen more clearly. Solutions can also be measured and then the spectrum of the solvent, which would otherwise overwhelm the experimental spectrum, to be removed.
Sources: en.wikipedia.org
== Alternative medicine == With the growth of direct-to-consumer genetic testing, the alternative medicine industry has aggressively targeted a range of dubious tests and highly profitable quack treatments for claimed MTHFR polymorphisms, despite the lack of any demonstrated health effects of these mutations. The promotion of supplements and other treatments for MTHFR polymorphisms, especially centered on autistic spectrum disorder, have been characterised as "snake oil". Tests for MTHFR, while gaining popularity, are generally unnecessary because the association of MTHFR gene mutations with various diseases have not been established as clear-cut cause-and-effect relationship.
Semax (Russian: СЕМАКС), an abbreviation of "seven amino acids", (Russian: СЕМь АминоКиСлот, romanized: Sem aminokislot) is a medication which is used in Eastern Europe for the treatment of a broad range of conditions like brain trauma but predominantly for its claimed nootropic, neuroprotective, and neurorestorative effects. The mechanism of action of Semax is unknown. It might interact with certain melanocortin receptors or inhibit enkephalinase enzymes. Chemically, Semax is a peptide and a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH). Semax was first described in scientific literature in 1991. Although used as a prescription drug in Russia, Semax has not been evaluated, approved for use, or marketed in most other countries. The drug is widely sold by online vendors and used as a purported nootropic (cognitive enhancer).
==== Myosin storage myopathy ==== In myosin storage myopathies, myosin accumulates beneath sarcolemma and between myofibrils, forming protein aggregates. A myopathy associated with the gene MYH7 is autosomal dominant myosin storage congenital myopathy-7A (CMYP7A).
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
电喷雾或基质辅助激光解吸电离质谱是常用手段，测得的质子化离子质荷比可换算为分子量。结果与理论值落在合理误差内，才支持结构一致的判断。